Emiliem Acquires World-Wide Rights to Develop and Commercialize a Novel Treatment for Cancer and Other Proliferative and Inflamm

Emiliem Acquires World-Wide Rights to Develop and Commercialize a Novel Treatment for Cancer and Other Proliferative and Inflammatory Diseases

4/23/2008

SAN FRANCISCO -- Emiliem, Inc. a privately-held biopharmaceutical company focused on discovering and developing novel molecular targeted therapeutics announced today that it has entered into an exclusive licensing agreement with the National Institutes of Health (NIH) for the world-wide rights to develop and commercialize a series of compounds that modulate key biological pathways known to be important in the progression of cancer and other proliferative and inflammatory diseases. The lead compound, which is positioned for clinical trials within a year, targets a key mechanism that determines whether cells, particularly those in tumors, grow and proliferate.

Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem stated, “This is a seminal moment in the history of our company. Not only do we gain a well-researched molecule at an advanced preclinical stage, but this also enables us to focus our internal discovery efforts including medicinal chemistry and early stage development activities around the PI3K/Akt/mTOR pathway, a series of biological events that control protein synthesis, angiogenesis, and cell cycle progression. Our on-going research on the chemical-biological mechanisms of action within this pathway and on the identification of patient-selection biomarkers will benefit the development of this molecule as well as the rest of our entire pipeline.”

Safe Harbor Statement

This document is intended to provide specific information regarding initiatives of Emiliem, Inc. It is not intended as a general advertisement nor an offer to sell or a solicitation of an offer to buy any securities or an interest in Emiliem, Inc. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information, matters described are forward-looking statements that involve risks and uncertainties, including: dependence on third parties for development, regulatory approval, and successful commercialization of products; the inherent risk of failure in developing product candidates based on new technologies; the risks associated with the cost of clinical development efforts, and other risks detailed in the company's private placement memorandum. Actual results may differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of release. The company disclaims any intent or obligation to update these forward-looking statements. 

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.